Piper Sandler Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $225
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG) and Penumbra (PEN)
Penumbra Is Maintained at Buy by Canaccord Genuity
Penumbra Analyst Ratings
CCORF Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $235
Penumbra's Strategic Progress and Earnings Growth Justify Buy Rating With $235 Price Target
Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Nurix Therapeutics (NRIX) and Charles River Labs (CRL)
BTIG Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $234
Maintaining Hold on Penumbra Amid Balanced Growth Prospects and Market Valuation
Penumbra Is Maintained at Buy by BTIG
Penumbra Price Target Raised to $235.00/Share From $200.00 by Truist Securities
Truist Financial Maintains Penumbra(PEN.US) With Buy Rating, Announces Target Price $235
BTIG Maintains Penumbra(PEN.US) With Buy Rating, Maintains Target Price $224
Buy Rating Affirmed: Penumbra's Market Potential Bolstered by THUNDER Trial and Thunderbolt Device Prospects
Penumbra Is Maintained at Outperform by RBC Capital
Penumbra Analyst Ratings
RBC Capital Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $222
Jefferies Maintains Penumbra(PEN.US) With Buy Rating, Cuts Target Price to $215
Jefferies Sticks to Its Buy Rating for Penumbra (PEN)
Stifel Maintains Penumbra(PEN.US) With Buy Rating, Maintains Target Price $238